In the Xenopus egg and oocyte system, oncogenic Ras protein can induce cell cycle arrest. The eect of oncogenic Ras on the cell cycle seems to be mediated by the Raf ± Mek ± Erk pathway of Ras signal transduction since constitutively active Raf, Mek, or Erk can mimic the eect of oncogenic Ras protein and since speci®c inhibition of these kinases can block the eect of oncogenic Ras. Using activated Xenopus egg extracts, we previously reported that the cell cycle arrest induced by oncogenic Ras correlates with the activation of a 96 kDa protein that phosphorylates histone h2b in vitro. This result raised the possibility that the 96 kDa kinase (designated as p96 h2bk ) is a potential target of the Raf ± Mek ± Erk pathway that links the pathway to the control of the cell cycle. We report here that constitutively active Mek1 could activate p96 h2bk in the absence of oncogenic Ras. Moreover, inhibition of endogenous Mek by a speci®c inhibitor, PD 098059, suppressed the activation of p96 h2bk by oncogenic Ras. These results are consistent with the concept that p96 h2bk is a component or target of the Raf ± Mek ± Erk pathway. Furthermore, we have shown that activation of p96 h2bk requires serine/threonine phosphorylation of p96 h2bk .
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Introduction
In Xenopus, microinjection of oncogenic Ras protein into fertilized eggs induces cell cycle arrest in the injected eggs (Daar et al., 1991) . Microinjection of oncogenic Ras protein into oocytes induces oocyte maturation (Birchemeier et al., 1985; Barrett et al., 1990; Pan and Cooper, 1990) , the G 2 -arrested oocytes reenter the cell cycle and then arrest at M-phase of meiosis. Thus, previous data have demonstrated that oncogenic Ras protein can exert an eect on the cell cycle.
In mammalian cells, at least three dierent Rasmediated signal transduction pathways have been identi®ed. The ®rst identi®ed pathway contains the Raf ± Mek ± Erk kinase cascade (reviewed by Crews and Erikson, 1993; Avruch et al., 1994; Daum et al., 1994; Khosravi-Far and Der, 1994; Cobb and Goldsmith, Hill and Treisman, 1995; Hunter, 1995; Marshall, 1995; Seger and Krebs, 1995) . In this pathway, activation of Ras activates the kinase Raf, which then phosphorylates and activates Mek1/Mek2 (also known as MAPKKs). The Meks in turn phosphorylate and activate Erk1/ Erk2 (also known as MAPKs). Erk1/Erk2 have a wide variety of substrates including the 90 kDa ribosomal S6 protein kinase (p90 rsk ) and transcriptional factors (reviewed by Blenis, 1993; Hill and Treisman, 1995) . Erk1/Erk2 activates p90 rsk by phosphorylation (reviewed by Blenis, 1993) . The second pathway involves another kinase cascade containing Jnk/Sapk (Jun Nterminal protein kinase/stress-activated protein kinase), a homolog of the MAPK protein family (reviewed by Davies, 1994; Hill and Treisman, 1995; Marshall, 1995) . Finally, a third pathway involves the phosphatidyinositol 3' kinase (Rodriguez-Viciana et al., 1994) . This pathway is less well characterized at present.
In the Xenopus oocyte or egg system, oncogenic Ras can activate Raf, Mek, p42 mapk (Erk2), and p90 rsk (Hattori et al., 1992; Pomerance et al., 1992; Shibaya et al., 1992; Nebreda et al., 1993; Fukuda et al., 1994) . Moreover, microinjection into oocytes or fertilized eggs of constitutively active Raf, Mek or p42 mapk induces maturation of oocytes (Fabian et al., 1993a; Muslin et al., 1993; Gotoh et al., 1995; Haccard et al., 1995; Huang et al., 1995; MacNicol et al., 1995) , or cell cycle arrest of fertilized eggs (Haccard et al., 1993) in the absence of oncogenic Ras. Furthermore, the eect of the oncogenic Ras on oocyte maturation can be suppressed by inhibition of the Raf activity by dominant-inhibitory Raf (Fabian et al., 1993a,b) or by the inhibition of the Mek activity by a neutralizing antibody (Fukuda et al., 1994) . These data together are consistent with the concept that the Raf ± Merk ± Erk pathway previously elucidated in mammalian cells also works in the Xenopus egg or oocyte system, and that the Raf ± Mek ± Erk pathway mediates the eect of oncogenic Ras on the cell cycle. It has been proposed that Mek ± Erk kinase cascade is required for Xenopus oocyte maturation (Kosako et al., 1994) and that the Raf ± Mek ± Erk pathway is involved in the control of the cell cycle progression in fertilized Xenopus eggs (MacNicol et al., 1995) .
Using activated Xenopus egg extracts (Lohka and Masui, 1983; Murray and Kirschner, 1989) , which are capable of undergoing cell-free cell cycling, we previously showed that oncogenic Ras induces cell cycle arrest in these extracts . Consistent with the idea that the Raf ± Mek ± Erk pathway mediates the eect of oncogenic Ras on the cell cycle, we demonstrated that oncogenic Ras activates p42 mapk and p90 rsk in activated egg extracts . Moreover, we also showed that cell cycle arrest by oncogenic Ras protein in activated egg extracts correlates with the activation of a 96 kDa kinase that phosphorylates histone H2b in vitro . The data raised the possibility that the 96 kDa histone H2b kinase (designated as p96 h2bk ) is a component or target of the Raf ± Mek ± Erk pathway that links this pathway to the control of the cell cycle by oncogenic Ras. We report here that p96 h2bk can be activated by constitutively active Mek1 and that the activation of p96 h2bk by oncogenic Ras can be inhibited by inhibition of endogenous Mek. Like other kinases of the Raf ± Mek ± Erk pathway, activation of p96 h2bk requires serine/threonine phosphorylation.
Results

Constitutively active Mek can activate p96 h2bk
We previously showed that activation of p96 h2bk correlates with the induction of cell cycle arrest during incubation of activated Xenopus egg extracts with oncogenic Ras. As discussed in the introduction, this result raised the question that p96
h2bk is a potential component or target of the Raf ± Mek ± Erk pathway that links this pathway to the control of the cell cycle by oncogenic Ras. We addressed whether p96 h2bk is a potential component or target for the Raf ± Mek ± Erk pathway. We reasoned that if activation of p96 h2bk by oncogenic Ras is mediated by the Raf ± Mek ± Erk pathway, then adding a constitutively active Mek to activated egg extracts would activate p96 h2bk in the absence of oncogenic Ras. Moreover, inhibition of endogenous Mek activity by a speci®c inhibitor would block the activation of p96 h2bk by oncogenic Ras. Activation of Mek1 by Raf kinase requires serine 218 and 222 residues (Alessi et al., 1994; Zhang and Guan, 1994) . Replacement of these two residues by aspartic or glutamic residues constitutively activates Mek1 (Hung and Erikson, 1994; Huang et al., 1995) . Microinjection of the constitutively active Mek1 (Mek DD), but not the wild type Mek1, was able to induce Xenopus oocyte maturation (Huang et al., 1995) , demonstrating that this mutant Mek mimics the eect of oncogenic Ras by activating the components downstream of Mek in the Raf ± Mek ± Erk pathway. We thus determined whether this mutant Mek can activate p96 h2bk in activated egg extracts in the absence of oncogenic Ras. We added puri®ed, baculovirusexpressed mutant Mek1 (Mek DD) (10 mg/ml extract), oncogenic Ras (2.5 mg/ml extract), or no exogenous protein (control) to three portions of an activated Xenopus egg extract. The extracts were then incubated at 258C. After various incubation periods, aliquots were subjected to the in-the-gel H2b kinase assay as described previously . For comparison, similar assays were performed on two additional portions of the extract incubated with puri®ed, wild type human Mek1 (10 mg/ml extract) (Cat#, sc-4025 Santa Cruz, CA) or with puri®ed, active wild type mouse Erk1 (10 mg/ml extract). Figure 1 shows the result. In comparison with the control extract, Mek DD was able to activate p96 h2bk in the absence of oncogenic Ras to similar levels as in extracts with added oncogenic Ras. (Alessi et al., 1995; Dudley et al., 1995) . To determine the eect of PD 098059 on the activation of p96 h2bk by oncogenic Ras, we added various amounts of PD 098059 to dierent portions of an activated egg extract to inhibit endogenous Mek. These extracts were then incubated with oncogenic Ras. At 90 min after the incubation, aliquots of these extracts were subjected to the in-thegel H2b kinase assay. For comparison, similar assays were also performed on additional portions of the extract incubated with MEK DD in the presence of PD 098059. The result is shown in Figure 2 . PD 098059 at a concentration of 10 mM was able to inhibit the majority of the activity of p96 h2bk by oncogenic Ras protein. This concentration is comparable to the reported concentration required for the inhibition of Mek1 in vitro (Alessi et al., 1995; Dudley et al., 1995) . This result showed that blocking the Raf ± Mek ± Erk pathway through the inhibition of endogenous Mek is able to suppress p96 h2bk activation by oncogenic Ras, demonstrating that activation of p96 h2bk by oncogenic Ras protein requires the activation of Mek.
It should be noted that Figure 2 (right panel) shows that PD 098059 had a weaker inhibitory eect on the activation of p96 h2bk by the constitutively active Mek. It has been reported that PD 098059 does not inhibit the phosphorylated Mek1, but inhibits the activation of Mek1 by preventing phosphorylation (Alessi et al., 1995) . The acidic residue substitution occurring to Mek DD may mimic the phosphorylation event. This 
Figure 1 Constitutively active Mek activates p96 h2bk in the absence of oncogenic Ras. To ®ve 100 ml aliquots of an activated egg extract, buer, oncogenic Ras (2.5 mg/ml), a mutant Mek1 (Mek DD) (10 mg/ml), wild type Mek1 (10 mg/ml), or wild type Erk1 (10 mg/ml) were added. The buer contained 88 mM NaCl, 20 mM HEPES, pH 6.8 and 50% ethylene glycol. After incubation at 258C, at 0, 45 and 90 min, aliquots were subjected to an in-the-gel H2b kinase assay as described previously by Mek DD. Moreover, it should also be noted that, in Figure 2 (left panel), a slightly higher level of p96 h2bk activity was detected at 100 mM PD 098059 than at 10 mM. It has been reported that PD 098059 inhibits the activation of Mek1 by Raf in vitro at an IC 50 value of 2 ± 7 mM (Alessi et al., 1995) . The 10 mM PD 098059 is close to the concentration required for a maximal inhibition. The slightly higher level of p96 h2bk activity that was detected at 100 mM PD 098059 than at 10 mM could be due to a small variation in the amounts of extracts loaded during electrophoresis (we applied proteins equivalent to 1 ml of the extracts to each lane during the SDS ± PAGE).
The above results are consistent with the concept that p96 h2bk is a component or a target of the Raf ± Mek ± Erk pathway that is in a position downstream of Mek. Whether p96 h2bk is downstream of Erk in the pathway was inconclusive, since the inability for the exogenous wild type Erk (Figure 1 , panel Erk) to activate p96 h2bk could be due to the inactivation of the active Erk by the phosphatases of the activated egg extracts Gotoh et al., 1995; Hunter, 1995) .
It should be noted that, in Figure 1 , although the p96 h2bk activity in the presence of exogenous Erk is little dierent from that of the control, the Erk seemed to slightly reduce p96 h2bk activity at the 90 min incubation point in comparison with those of the 0 and 45 min incubation points (compare lane 90 min with lanes 0 and 45 min in panel Erk). However, this slight reduction in activity was not detected in another similar experiment, suggesting that this reduction was not due to the possible downregulation of p96 h2bk activity by the Erk.
Okadaic acid activates p96 h2bk in activated Xenopus egg extracts
As discussed in the Introduction, activation of the component kinases of the Raf ± Mek ± Erk pathway requires phosphorylation. It is possible that activation of p96 h2bk by oncogenic Ras also requires phosphorylation of p96 h2bk . To address this possibility, we reasoned that if serine/threonine phosphorylation is required, then adding a speci®c inhibitor of some serine/ threonine phosphatases to activated Xenopus egg extracts, to prevent potential serine/threonine dephosphorylation of p96 h2bk , may result in the activation of p96 h2bk . Moreover, adding a serine/threonine phosphatase to activated egg extracts preincubated with oncogenic Ras, should cause inactivation of p96 h2bk . Furthermore, dephosphorylation of puri®ed, active p96 h2bk by serine/threonine phosphatases should inactivate the kinase.
We ®rst investigated whether okadaic acid can activate p96 h2bk in activated egg extracts in the absence of oncogenic Ras. Okadaic acid is a speci®c inhibitor of serine/threonine phosphatase 1 (PP1) and serine/ threonine phosphatase 2A (PP2A) (Bialojan and Takai, 1988; Cohen, 1989) . We ®rst determined whether adding okadaic acid to activated egg extracts can activate protein kinase(s) that phosphorylate histone H2b in vitro. Various concentrations of okadaic acid were added to portions of an activated Xenopus egg extract. Aliquots were sampled after incubation at 258C for 90 min and assayed for H2b kinase activity by incubating the samples with [ 32 P]ATP and a histone preparation containing histone H2b. After the incubation, the mixtures were subjected to SDS ± PAGE and autoradiography. For comparison, another two portions of the extract were incubated with or without
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Figure 2 PD 098059 inhibits the activation of p96 h2bk by oncogenic Ras. Aliquots (each 20 ml) of an activated egg extract were added with either buer solution (control), oncogenic Ras (2.5 mg/ml), oncogenic Ras (2.5 mg/ml extract) plus 10 mM or 100 mM PD 098059 (Research Biochem. Ma), Mek DD (10 mg/ml extract) or Mek DD plus 10 mM or 100 mM PD 098059. These extracts were then incubated at 258C for 90 min. Aliquots were subjected to the in-the-gel H2b kinase assay Figure 3a shows that, like oncogenic Ras (Figure 3a , right panel), okadaic acid alone (Figure 3a , left panel) induced a kinase activity that phosphorylated histone H2b in vitro. Okadaic acid at a concentration below 0.4 mM was ineective in activating the H2b kinase(s); however, okadaic acid at 0.8 mM fully activated the H2b kinase(s). We did not detect any further increase in H2b kinase activity even when 50 mM okadaic acid was used (not shown). This result demonstrated that okadaic acid alone is able to activate protein kinase(s) in activated egg extracts to phosphorylate histone H2b in vitro. We then further determined whether p96 h2bk was activated by okadaic acid in these samples. We subjected aliquots of the above samples to the in-the-gel H2b kinase assay as described previously . Figure 3b shows the result. Like oncogenic Ras (Figure 3b , right panel), okadaic acid alone (Figure 3b, left panel) . We then added a buer solution containing no PP2A (untreated control), PP2A, or PP2A plus 1 mM okadaic acid to three diluted portions of the extract. Samples after various incubation periods at 258C were assayed for p96 h2bk activity using the in-the-gel H2b kinase assay. Figure 4a shows that, in comparison with the untreated control incubation (panel control), PP2A treatment (panel PP2A) completely abolished the activity of p96 h2bk . Moreover, the action of PP2A was prevented if 1 mM okadaic acid was present to inhibit the phosphatase during the incubation (Figure 4a , panel PP2A+OA). Figure 4b is a Coomassie bluestained result showing that the decrease in p96 h2bk activity after the phosphatase treatment was not due to protein degradation. These results suggest that serine/threonine dephosphorylation can inactivate p96 h2bk in activated Xenopus egg extracts that have been incubated with oncogenic Ras.
Taken together, all the above results suggest that serine/threonine phosphorylation is involved in the activation of p96 h2bk by oncogenic Ras in activated egg extracts.
Protein phosphatase 1 and phosphatase 2A inactivate puri®ed, active p96 h2bk
The above experiments were performed in egg extracts. The eects of okadaic acid and the exogenous pp2A are thus very possibly indirect. For example, okadaic acid may activate p96 h2bk by inactivating a phosphatase dephosphorylating and inactivating an upstream activator of p96 h2bk ; the exogenous PP2A may inactivate p96 h2bk through the dephosphorylation and inactivation of an upstream activator of p96 h2bk . We thus determined the eects of serine/threonine protein phosphatases PP1 or PP2A on the activity of puri®ed p96 h2bk . We puri®ed active p96 h2bk by fractionation by SDS ± PAGE of activated Xenopus egg extracts that had been preincubated with oncogenic Ras. We then added a buer solution containing no PP1 (untreated control), PP1, or PP1 plus 100 nM okadaic acid to three . After various incubation periods at 258C, samples were subjected to the in-the-gel H2b kinase assay. Figure 5a shows that, in comparison with the untreated control (panel control), PP1 treatment (panel PP1) completely abolished the H2b kinase activity of the p96 h2bk . Moreover, the abolishment of the kinae activity by PP1 was prevented if 100 nM okadaic acid was coincubated with p96 h2bk (Figure 5a , panel PP1+OA). Similar results were obtained when PP2A was used to treat the active p96 h2bk fraction (Figure 5b ). In addition, the result of the Coomassie blue stain for the samples from the phosphatase 2A treatment experiment showed that the amounts of total proteins in the p96 h2bk fraction remained unchanged during the incubation periods ( Figure 5c , the bands between the 110 kDa and the 71 kDa molecular weight markers). Taken together, these results indicated that the abolishment of the activity of p96 h2bk was not caused by protein degradation but rather by serine/threonine dephosphorylation by the phosphatases. Furthermore, the p96 h2bk fraction . Active p96 h2bk was fractionated by SDS ± PAGE of 1 ml of activated egg extracts preincubated with oncogenic Ras as described in the Materials and methods. The fractionated p96 h2bk was extensively dialyzed as described in the Materials and methods. Three aliquots (each 100 ml) of this solution, each containing p96
h2bk from 50 ml of egg extracts, were incubated at 258C with no protein phosphatase 1, 1 ml of protein phosphatase 1 (0.2 units/ml) (cat# 14-110, Upstate Biotech, NY), or 1 ml of protein phosphatase 1 plus 100 nM of okadaic acid. After incubation for 0, 30, 60 and 90 min, samples were subjected to the in-the-gel H2b kinase assay. (Figure 5c , the bands between the 110 kDa and the 71 kDa molecular weight markers), suggesting that the abolishment of the kinase activity was probably due to the inactivation of p96 h2bk by a direct serine/threonine dephosphorylation of p96 h2bk by the PP1 or PP2A. p96 h2bk may not be a direct substrate for Mek or Erk
The kinase in the Raf ± Mek ± Erk pathway that is directly responsible for the activation of p96 h2bk remains unclear. Since p96 h2bk can be activated in activated extracts by constitutively active Mek1, it is possible that p96 h2bk could be a direct substrate for Mek or Erk. To address this question, we incubated Mek DD or an active Erk with inactive p96 h2bk in the presence of okadaic acid and ATP. The inactive p96 h2bk was prepared from active p96 h2bk , puri®ed by SDS ± PAGE as described above, by treatment with PP2A. Figure 6a shows that neither Mek DD nor active Erk was able to reactivate p96 h2bk . Figure 6b shows that both the Mek DD and the Erk were active. h2bk ; however, this inactivation was blocked if okadaic acid was present during the treatment. Overall, our results are consistent with the concept that p96 h2bk is a target or component of the Raf ± Mek ± Erk pathway that is activated by serine/threonine phosphorylation.
It is important to note that although our results are consistent with the possibility that p96 h2bk is directly activated by oncogenic Ras through a kinase of the Raf ± Mek ± Erk pathway, it is also possible that activation of p96 h2bk by oncogenic Ras involves the inactivation of a serine/threonine phosphatase. The observation that inactivation of serine/threonine phosphatases by okadaic acid was able to activate p96 h2bk is consistent with the concept.
In conclusion, our results are consistent with the concept that p96 h2bk is a potential component or target for the Raf ± Mek ± Erk pathway. As discussed above, the Raf ± Mek ± Erk pathway is responsible for the cell cycle arrest induced by oncogenic Ras. It is possible that p96 h2bk functions to link this pathway to the control of the cell cycle. We have previously shown that the induction of the cell cycle arrest by oncogenic . Active p96 h2bk was fractionated by SDS ± PAGE from an extract preincubated with oncogenic Ras, and the p96 h2bk -containing fraction was then extensively dialyzed as described above. A portion of the p96 h2bk -containing solution was treated with PP2A for 60 min to inactivate p96 h2bk as described above. Okadaic acid (1 mM) was then added to inactivate the PP2A. Four 50 ml aliquots (each contained p96 h2bk equivalent to 50 ml of egg extracts) of the PP2A-treated, okadaic acid-added p96 h2bk solution were then incubated with either no added kinase, active Erk (50 mg/ml), Mek DD (50 mg/ ml), or active Erk (50 mg/ml) and Mek DD (50 mg/ml) in the presence of a buer containing 1 mM ATP, 2.5 mM MgCl 2 , 2.5 mM DTT, 10 mg/ml leupeptin, and 20 mM HEPES, pH 7.8. As a control, an aliquot of the original p96 h2bk solution, which was not treated with PP2A and okadaic acid, was similarly incubated. Aliquots from these mixtures were then subjected to the in-thegel-H2b kinase assay. . Cdc2 is a cyclin-dependent protein kinase that controls the cell cycle (Nurse, 1990) . It is possible that p96 h2bk links the Raf ± Mek ± Erk pathway to the control of cyclin-dependent protein kinases by oncogenic Ras.
Materials and methods
Preparation and incubation of activated Xenopus egg extracts
Activated Xenopus egg extracts were prepared and incubated with oncogenic human RasH protein (61-leu) (Pan and Cooper, 1990 ) and other reagents as described previously . Some of the extracts were frozen as 7808C and were thawed before use.
Partial puri®cation of active p96
h2bk from activated Xenopus egg extracts p96 h2bk in activated Xenopus egg extracts was activated by incubating the extracts with puri®ed, bacterially-expressed oncogenic human RasH (61-leu), as described previously . p96 h2bk was partially puri®ed from these extracts by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS ± PAGE) (Laemmli, 1970) . Brie¯y, activated egg extracts were incubated with oncogenic Ras at a concentration of 0.5 mg/ml extract to 2.5 mg/ml extract at 258C for 120 min. The extracts were then subjected to centrifugation at 200 k6g in a SW55Ti rotor for 2 h. The supernatants were collected and subjected to SDS ± PAGE. Bands approximately 0.5 cm wide corresponding to the 96 kDa region (between the 110 kDa and the 71 kDa molecular weight markers) were cut out of the gels and subjected to electroelution in electrophoresis buer. The eluted proteins were extensively dialyzed against a buer containing 0.05% mercaptoethanol and 20 mM HEPES, pH 7.8, followed by another buer containing 100 mM KCl, 1 mM MgCl 2 , 1 mM dithiothreitol (DTT), 10 mg/ml leupeptin, and 20 mM HEPES, pH 7.8. The dialyzed protein solution contained active p96 h2bk , as judged by the in-the-gel H2b kinase assay, and contained only a few Coommassie blue-stained protein bands (see Figure 5c ).
The H2b kinase assay and the in-the-gel H2b kinase assay The H2b kinase assay The H2b kinase assay was performed as described previously . Brie¯y, activated egg extracts were diluted twenty times in buer A containing 100 mM KCl, 80 mM b-glycerophosphate, 15 mM MgCl 2 , 20 mM EGTA and 20 mM HEPES, pH 7.8. Ten microliters of the diluted extracts was incubated with an equal volume of buer A containing 0.2 mM ATP, 1 mCi [ 32 P]ATP and 1 mg/ml of calf thymus histone HF1 fraction or HF2b fraction (Worthington Biochem, NJ), which contains histone H2b, at 308C for 10 min. The mixtures were then subjected to SDS ± PAGE and autoradiography.
The in-the-gel H2b kinase assay The in-the-gel H2b kinase assay was performed according to a method we described previously . Brie¯y, aliquots of egg extract or aliquots of solution containing puri®ed p96 h2bk were subjected to SDS ± PAGE in gels containing 0.4 mg/ ml of calf thymus histone H2b. The gels were incubated with 20% isopropranol and then treated with 6 M guanidine HCl. After the gels had been washed, 50 mM [ 32 P]ATP was added to initiate kinase reaction. After extensive washing in a solution containing 5% trichloroacetic acid and 1% sodium pyrophosphate, the gels were subjected to autoradiography.
Erk and Mek assays
The Erk assay The Erk assay was performed as follows. A total 20 ml solution, containing 10 mg/ml of Erk, 1 mg/ml of myelin basic protein (MBP) (Sigma), 100 mM of ATP, 0.5 mCi [ 32 P]ATP, 2.5 mM MgCl 2 , 2.5 mM DTT and 20 mM Tris, pH 7.4, was incubated at 308C for 30 min. An aliquot was then subjected to SDS ± PAGE and autoradiography.
The Mek assay The Mek assay was performed as follows. A constitutively active Mek (Mek DD) (10 mg/ml) was incubated with 20 mg/ml of an inactive Erk in a total 10 ml solution containing 100 mM of ATP, 2.5 mM MgCl 2 , 2.5 mM DTT and 20 mM Tris, pH 7.4. After incubation at 308C for 30 min, a 10 ml solution containing 1 mCi [ 32 P]ATP and 2 mg/ml of MBP was added to the mixture. The mixture was further incubated at 308C for 30 min. An aliquot was then subjected to SDS ± PAGE and autoradiography.
Erk and Mek proteins
The mutant Mek1 protein (asp-218 and asp-222) (Mek DD) was puri®ed from Sf9 cells infected with baculovirus carrying the mutated mouse mek1 gene (asp-218 and asp-222) C-terminally tagged with the EE epitope (Rubinfeld et al., 1991; Hung and Erikson, 1994; Huang et al., 1995) . The puri®ed wild type Erk1 protein was active (active Erk) and was produced as a fusion protein of glutathione S-transferase and mouse Erk1 (Crews et al., 1991) . These proteins were in a buer containing 88 mM NaCl, 20 mM HEPES, pH 6.8 and 50% ethylene glycol. Wild type human Mek1 protein, produced as a polyhistidine tagged fusion protein, was purchased from Santa Cruz Biotech, CA (cat# sc-4025). Inactive Erk, produced as a fusion protein of glutathione S-transferase and Xenopus Erk (p42 mapk ) in bacteria, was purchased from Santa Cruz Biotech (cat# 4024).
